李氏大藥廠Lee's Pharm
李氏大藥廠控股有限公司(「李氏大藥廠」或「集團」)是一家已上市生物醫藥公司,于中國醫藥行業經營超過18年。集團擁有國際視野并結合已在中國建立了穩固的藥品發展、臨床發展、規管、制造及銷售以及市場推廣的業務模式,目前在中國推出市場的產品共有十一種。李氏大藥廠致力于不同范疇,包括心血管及傳染疾病、皮膚醫學、腫瘤學、婦科學等多個不同領域。而其它處于不同開發階段產品亦有超過三十種,包括來自內部研發及近期購買各美國, 歐洲公司及日本的特許及分銷權。于二零一零年,李氏大藥廠更獲亞洲財經雜志《Finance Asia》頒發「2010亞洲最佳公司選舉 – (中國區)最佳小型企業」第二名。 于2011年9月李氏大藥廠獲福布斯選為亞洲最佳二百公司(營業額少于十億美元)。 李氏大藥廠的目標是成為亞洲成功的生物醫藥集團,提供能治療疾病,同時改善身體及生活素質。
李氏大藥廠的策略性股東,Sigma Tau Group是羅馬(意大利)國際領先的醫藥研究公司。Sigma Tau 進行的研發活動和商業技術與李氏大藥廠現時的業務有互補的作用,為李氏大藥廠帶來重要的業務協同效益。
Lee's Pharmaceutical Holdings Limited (Lee's Pharm or “the Group”) is a public biopharmaceutical company with over 18 years operation in China's pharmaceutical industry. It is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales and marketing in China with global perspectives and currently markets eleven products in the PRC. Lee's Pharm focuses on several different areas such as cardiovascular and infectious diseases, dermatology, oncology, gynecology and others. It has more than 30 products under different development stages stemming from both internal R&D as well as from the recent acquisition of licensing and distribution rights from various US, European and Japanese companies. In 2010, Lee’s Pharm ranked as Best Small-Cap Company in China (Rank 2nd) by Finance Asia. In September 2011, Lee's Pharm has been selected by Forbes as one of Asia's 200 Best Under A Billion Company (turnover less than US$1 billion). The mission of Lee's Pharm is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life.
Sigma Tau Group, the leading research-based international pharmaceutical company based in Rome (Italy), is a strategic shareholder of Lee's Pharm. Sigma Tau's ongoing R&D activities and commercial know-how are complementary to the existing business activities of Lee's Pharm and will result in creating significant business synergies for Lee's Pharm.